Summary

for people ages 18-75 (full criteria)
at La Jolla, California and other locations
study started
estimated completion:
Edward Ball

Description

Summary

The purpose of this project is to develop a process to identify highly personalized antigens that are uniquely expressed by the patient's own leukemia cells that can be used for cellular immune therapy.

Official Title

Bone Marrow and Peripheral Blood (PB) Samples From Patients With Leukemia and PB From Their BM Donors (BMD) to Identify Leukemia-Specific Antigens (LSA) and Graft Versus Host Disease Antigens (GVHDA) for Use in Cellular Immunotherapy

Details

It is well known that tumor cells and leukemia cells express different surface structures (called antigens) that can serve as targets for cancer cell destruction by the immune system. Effective immune therapies are characterized by high specificity and low toxicity. One of the major obstacles impeding the use of these therapies as standard of care is the identification of good target antigens. In acute myeloid leukemia (AML) there is major patient to patient variation in leukemia antigens, so there is no universal AML cell target. Rather, each patient has a unique array of potential cell targets. Thanks to the rapid progress of new DNA/RNA sequencing technologies, the identification of these unique, patient-specific leukemia cell antigen-targets is now possible.

The purpose of this project is to develop a process to identify highly personalized antigens that are uniquely expressed by the patient's own leukemia cells that can be used for cellular immune therapy.

Keywords

Acute Myeloid Leukemia Acute Leukemia AML Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute

Eligibility

You can join if…

Open to people ages 18-75

  • Diagnosis of AML with plan to receive a bone marrow transplant

You CAN'T join if...

Locations

  • University of California San Diego accepting new patients
    La Jolla California 92093 United States
  • Northside Hospital accepting new patients
    Atlanta Georgia 30342 United States

Lead Scientist

  • Edward Ball
    Dr. Ball’s research focuses on the development of monoclonal antibody (mAb)-targeted immunotherapy and its translation to the treatment of patients with malignancy. His lab produced mAbs to myeloid-associated antigens expressed on myeloid leukemia cells.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
PersImmune, Inc
ID
NCT02667093
Study Type
Observational
Last Updated